References.

[1]. Ruggiero A, Trombatore S, Triarico R, Arena R, Ferrara M, Scalzone M, Pierri F, Riccardi R. Platinum compounds in children with cancer: toxicity and clinical management. Anti Canc Drugs 2013; 24. 1007–1019
[2]. Knight KR, Kraemer DF, Neuwelt, EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 2012;23:8588–8596
[3]. Bass JK, Huang J, Onar-Thomas A, Chang K W, Bhagat SP, Chintagumpala M, Bartels U, Gururangan S, Hassall T, Heath JA, McCowage G, Cohn RJ, Fisher MJ, Robinson G, Broniscer A, Gajjar A, Gurney JG. Concordance between the Chang and the International Society of Pediatric Oncology (SIOP) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediat Blood Cancer (2014); 61:601–605
[4]. Peleva E., Emami N., Alzahrani M., Bezdjian A., Gurberg J., Carret AS, Daniel SJ. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec. Pediatr Blood Cancer 2104; 61:2012–2017
[5]. Davis J M, Elfenbein J, Schum R, Bentler R A. Effects of mild and moderate hearing impairments on language, educational, and psychosocial behaviour of children. J Speech Hear Disord 1986; 51:53–62
[6]. Gurney J.G., Tersak J.M., Ness K.K., Landier W., Matthay K.K., Schmidt ML, Children’s Oncology Group. Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: a report from the Children’s Oncology Group. Pediatrics 2007; 120:e1229–1236
[7]. Schreiber JE, Gurney JG, Palmer SL, Bass J K., Wang M, Chen S, Zhang H, Swain M, Chapieski ML, Bonner MJ:, Mabbott DJ. Knight SJ., Armstrong CL, Boyle B, Gajjar A. Examination of risk factors for intellectual and academic outcomes following treatment for paediatric medulloblastoma. Neuro Oncol 2014; 16:1129–1136
[8]. Brooks B, Knight K. Ototoxicity monitoring in children treated with platinum chemotherapy. Int J Audiol 2018; 57:S34–S40
[9]. Fetoni AR, Paciello F, Rolesi R, Paludetti G, Troiani D. Targeting dysregulation of redox homeostasis in noise-induced hearing loss: Oxidative stress and ROS signaling. Free Radic Biol Med 2019; 135:46–59
[10]. Paciello F, Fetoni A R, Mezzogori D, Rolesi R, Di Pino A, Paludetti G, Grassi C, Troiani D. The dual role of curcumin and ferulic acid in counteracting chemoresistance and cisplatin-induced ototoxicity. Sci Rep 2020; 10:1063-1067
[11]. Takeno S, Harrison RV, Ibrahim D, Wake M, Mount RJ.Cochlear function after selective inner hair cell degeneration induced by carboplatin. Hear Res 1994;75:93–102
[12]. Punnett A, Bliss B, Dupuis LL, Abolell M, Doyle J, Sung L. Ototoxicity following pediatric hematopoietic stem cell transplantation: a prospective cohort study. Pediatr Blood Cancer (2014) 42:598–603
[13]. Qaddoumi I, Bass J K, Wu J, Billups CA, Wozniak AW, Merchant TE, Haik BG, Wilson MW, Rodriguez-Galindo C. Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 2012; 30:1034–1041
[14]. Fetoni AR, Paciello F, Mezzogori D, Rolesi R, Eramo SL, Paludetti G, Troiani D. Molecular targets for anticancer redox chemotherapy and cisplatin-induced ototoxicity: the role of curcumin on pSTAT3 and Nrf-2 signalling. Br J Cancer 2015; 113:1434–1444
[15]. Fetoni A R, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G, Paludetti G. Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurootol 2016; 21:203–211
[16]. Kalkanis JG, Whitworth C, Rybak LP. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 2004; 114:538–542
[17]. Choe W. T., Chinosornvatana N., Chang K. W. (2004), Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate, Otol. Neurotol., 25:910–915
[18]. Grewal S, Merchant T, Reymond R, Hodge C M, Shearer P. Auditory late effects of childhood cancer therapy: A report from the Children’s Oncology Group. Pediatrics 2010; 125:e938–950
[19]. Olgun Y, Kırkım G, Kolatan E, Kıray M, Bagrıyanık A, Olgun A, Kızmazoglu DC, Ellıdokuz H, Serbetcıoglu B, Altun Z, Aktas S, Yılmaz O, Günerı EA. Friend or foe? Effect of oral resveratrol on cisplatin ototoxicity. Laryngoscope 2014; 124:760–766
[20]. Hughes L, Hussain N, Pafford R, Parham K. Dexamethasone otoprotection in a multidose cisplatin ototoxicity mouse model. Otolaryngol Head Neck Surg 2014; 150:115–120
[21]. Marshak T, Steiner M., KaminerM, Levy A, Shupak A. Prevention of cisplatin-induced hearing loss by intratympanic dexamethasone: a randomized controlled study. Otolaryngol Head Neck Surg 2014; 50:983–990
[22]. Laurell G. Pharmacological intervention in the field of ototoxicity. HNO 2019; 67:434–439
[23]. Audiologic management of individuals receiving cochleotoxic drug therapy. Guidelines developed by the American Speech-Language-Hearing Association (ASHA), 1994; 36(supplement 12):11–19
[24]. Stavroulaki P, Apostolopoulos N, Segas J, Tsakanikos M, Adamopoulos G. Evoked otoacoustic emissions–an approach for monitoring cisplatin induced ototoxicity in children, Int J Pediatr Otorhinolaryngol 2011; 59:47–57
[25]. Romano A, Capozza MA, Mastrangelo S. Maurizi P, Triarico S, Rolesi R, Attinà G, Fetoni AR, Ruggiero A. Assessment and management of platinum-related ototoxicity in children treated for cancer, Cancers (Basel), 2020; 2:E1266
[26]. Konrad-Martin D, Helt DJ, Reavis KM, Ototoxicity: early detection and monitoring. ASHA Leader 2004; 10:1–14
[27]. Jacob BCB, Aguiar FP, Tomiasi AA, Tschoeke SN, De Bitencourt RF. Auditory monitoring in ototoxicity. Braz J of Otorhinolaryngol 2006; 72:836–844
[28]. Nitz A, Kontopantelis E, Bielack S, Koscielniak E, Klingebiel T, Langer T, Paulides M, Prospective evaluation of cisplatin- and carboplatin-mediated ototoxicity in paediatric and adult soft tissue and osteosarcoma patients. Oncol Lett 2013;5:311–315
[29]. Bertolini P, Lassalle M, Mercier M, Raquin MA, Izzi G, Corradini N, Hartmann O. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 2004; 26:649–655
[30]. Al-Khatib T, Cohen N, Carret AS, Daniel S. Cisplatinum ototoxicity in children, long-term follow-up. Int J Pediatr Otorhinolaryngol 2010; 74:913–919
[31].Einarsson EJ, Petersen H, Wiebe T, et al. (2010), Long-term hearing degeneration after platinum-based chemotherapy in childhood, Int J Audiol 2010; 49:765–771
[32]. Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass LK, Kuehni CE, Langer T, C van Dalen E, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, International Guideline Harmonization Group ototoxicity group. International Guideline Harmonization Group ototoxicity group. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 2019; 20:e29–41
[33]. Gietema JA, Meinardi MT, Messerschmidt J, Gelevert T, Alt F, Uges DR, Sleijfer DT. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 2000; 25;355(9209):1075–6
[34].Lu J, Wang W, Liu H, Wu H. Cisplatin induces calcium ion accumulation and hearing loss by causing functional alterations in calcium channels and exocytosis. Am J Transl Res 2019; 11:6877–6889
[35]. Sheth S, Sheehan K, Dhukhwa A, Al Aameri RFH, Mamillapalli C, Mukherjea D, Rybak LP, Ramkumar V. Oral administration of caffeine exacerbates cisplatin-induced hearing loss. Sci Rep 2019; 9:9571-95
[36]. Liberman MC, Kujawa SG. Cochlear synaptopathy in acquired sensorineural hearing loss: manifestations and mechanisms. Hear Res 2017;349:138–147
[37]. Skinner R. Best practice in assessing ototoxicity in children with cancer. Eur J Cancer 2004; 40:2352–4
[38]. Dean JB, Hayashi SS, Albert CM, King AA, Karzon R, Hayashi RJ. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol 2008; 30:130–4
[39]. Tserga E, Nandwani T, Edvall NK, Bulla J, Patel P, CanlonB, Cederroth CR, Baguley DM. The genetic vulnerability to cisplatin ototoxicity: a systematic review. Sci Rep 2019; 9:3455, doi: 10.1038/s41598-019-40138-z
[40]. Waissbluth S, Chuang A, Del Valle A, Cordova M. Long-term platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol 2018;107:75–79
[41]. Wei M, Yuan X. Cisplatin-induced ototoxicity in children with solid tumor. J Pediatr Hematol Oncol 2019; 41:e97–e100
[42]. Hamilton SH, Arshad O, Kwok J, Tran E, Howard AF, Serrano I, Goddard K. Documentation and incidence of late effects and screening recommendations for adolescent and young adult head and neck cancer survivors treated with radiotherapy. Supp Care Cancer 2019; 27:260 9‐2616
[43]. Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink MM,Carleton B. A comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAEv4.03 ototoxicity grading scales applied to 3,799 audiograms of childhood cancer patients treated with platinum-based chemotherapy. PLoS One 2019;14:e0210646
[44]. Kral A, Dorman MF, Wilson BS. Neuronal development of hearing and language: cochlear implants and critical periods. Ann Rev Neurosci 2019; 42:47–65
[45]. Weiss A, Sommer G, Schindera C, Wengenroth L, KarowA, Diezi M, Michel G, Kuehni EC, Swiss Paediatric Oncology Group (SPOG). Hearing loss and quality of life in survivors of paediatric CNS tumours and other cancers. Qual Life Res 2019; 28:515–521